Journal: Diabetes Spectrum : A Publication of the American Diabetes Association

Article Title: Why Download Data: The Benefits and Challenges of More Diabetes Data

doi: 10.2337/ds18-0099

Figure Lengend Snippet: Comparison of Diabetes Devices Compatible With Tidepool and Glooko

Article Snippet: Animas OneTouch Ping, Vibe Tandem t:slim, t:slim G4, t:slim X2, t:flex Insulet OmniPod Roche Spirit, Spirit Combo, Accu-Chek Insight ViCentra Kaleido Ypsomed mylife OmniPod CGM systems Abbott FreeStyle Navigator II FreeStyle Libre Dexcom G5 Mobile, G5 Mobile (Dexcom online), G4 Platinum Senseonics Eversense CGM Transmitter Blood glucose meters A complete list is available on Tidepool’s website at tidepool.org/users/devices A complete list is available on Glooko’s website at www.glooko.com/ compatibility Open in a separate window Comparison of Diabetes Devices Compatible With Tidepool and Glooko American Association of Clinical Endocrinologists and American College of Endocrinology guidelines recommend that insulin pump and CGM data should be downloadable on the same platform and displayed in the context of meals, exercise, illness, and insulin boluses ( 7 , 12 ).

Techniques:

Journal: Oncology letters

Article Title: LAMP2A overexpression in colorectal cancer promotes cell growth and glycolysis via chaperone‑mediated autophagy.

doi: 10.3892/ol.2023.14164

Figure Lengend Snippet: Figure 4. LAMP2A protects colorectal cancer cells from oxidative damage and promotes colorectal cancer cell drug resistance. (A) Colorectal cancer cells with different LAMP2A expression levels were treated with H2O2 (0, 0.2, 0.4 and 0.8 µM) for 36 h and cell viability was measured by MTT assay. (B) Colorectal cancer cells with different LAMP2A expression levels were treated with oxaliplatin (0, 1, 2 and 3 µmol/l) for 36 h and cell viability was measured by MTT assay. All values are the means ± SDs of three different experiments; *P<0.05, **P<0.01. LAMP2A, lysosome‑associated membrane protein type 2A.

Article Snippet: For the oxaliplatin, H2O2 or 2‐deoxy‐D‐glucose (2‐DG) treatment assay, SW480 and HT29 cells (1x104/well) were seeded onto a 96‐well plate and treated with oxaliplatin (Selleck Chemicals; 0, 1, 2 and 3 μmol/l), H2O2 (0, 0.2, 0.4 and 0.8 μM) or 5 mmol/l 2‐DG for 36 h. Wound healing assay.

Techniques: Expressing, MTT Assay, Membrane

Journal: Oncology letters

Article Title: LAMP2A overexpression in colorectal cancer promotes cell growth and glycolysis via chaperone‑mediated autophagy.

doi: 10.3892/ol.2023.14164

Figure Lengend Snippet: Figure 6. LAMP2A promotes glycolysis in colorectal cancer cells. (A) ECAR was detected in colorectal cancer cells after LAMP2A knockdown or overexpres sion, followed by injection of (vertical line) glucose (25 mM), oligomycin (1 µM) and 2‑DG (50 mM). (B) Lactate levels in the culture medium of colorectal cancer cells with different LAMP2A expression levels were determined using an L‑lactate assay kit. (C) Lactate production and (D) cell viability were measured after SW480 cells were treated with 2‑DG (5 mM) and oxaliplatin (2 µmol/l) for 36 h. n=3, *P<0.05, **P<0.01. ECAR, extracellular acidification rate; LAMP2A, lysosome‑associated membrane protein type 2A.

Article Snippet: For the oxaliplatin, H2O2 or 2‐deoxy‐D‐glucose (2‐DG) treatment assay, SW480 and HT29 cells (1x104/well) were seeded onto a 96‐well plate and treated with oxaliplatin (Selleck Chemicals; 0, 1, 2 and 3 μmol/l), H2O2 (0, 0.2, 0.4 and 0.8 μM) or 5 mmol/l 2‐DG for 36 h. Wound healing assay.

Techniques: Knockdown, Injection, Expressing, Membrane